Prevent preclinical drug development program: preclinical efficacy and intermediate biomarkers (POP: 1/25/2019 - 1/24/2024)
Ended Awarded Last action
- Contract number
- 75N91019D00021
- Awardee
-
The Univeristy Of Texas M.d. Anderson Cancer Center UEI S3GMKS8ELA16 Part of University Of Texas System
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Task orders
- 13 $12,529,369 obligated
Award facts
- Opportunity
-
- PREVENT Cancer Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Biomarker Endpoints, Preclinical Services for Biopharmaceutical Product Development and Manufacturing, and Toxicology and Pharmacology Testing Pre-Solicitation · N01CN7701918 · Posted Apr 19, 2018
- PREVENT Cancer Preclinical Drug Development Program Award Notice · Posted May 7, 2018
- Combined order value
- $13,778,484 Current and potential, with all options
- Last date to order 100% complete
- IDV ceiling 17% used
- $74,995,000.00
- Award type
- Multiple award
- Who can order
- Only the awarding agency
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 4 offers Negotiated Proposal / Quote
- Pricing
- Order Dependent (IDV only)
- Legislative mandates
-
- Walsh-Healey Public Contracts Act FAR subpart 22.6
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this IDV
The National Cancer Institute awarded a multiple-award indefinite delivery contract to The University of Texas M.D. Anderson Cancer Center on January 25, 2019, with a ceiling value of $74,995,000 and ultimate completion date of January 24, 2024, for the PREVENT Preclinical Drug Development Program focused on preclinical efficacy testing and intermediate biomarker evaluation of cancer preventive agents. Work is performed in Houston, Texas.
The IDIQ supports systematic preclinical evaluation of potential cancer preventive drugs and vaccines across multiple disease sites, including colorectal, pancreatic, breast, lung, multiple myeloma, and hepatocellular carcinoma. The originating solicitation sought proposals across three service pools: preclinical efficacy and biomarker evaluation, preclinical Good Manufacturing Practice product development and manufacturing, and toxicology and pharmacology testing. Up to 20 multiple-award IDIQs were awarded across the three pools, with NAICS codes 541715 and 541712 and PSC code R408. Task orders under this vehicle carry firm fixed-price pricing and require services including preclinical drug testing on 50–100 agents annually across 50–150 studies.
Recent task order activity issued under this IDIQ includes delivery orders addressing targeting the A2B adenosine receptor for pancreatic cancer immunoprevention ($1,272,481, September 2023), further development of iPSC-based vaccine for colon cancer prevention ($1,293,012, July 2023), targeting DKK1 with a DNA vaccine for multiple myeloma prevention ($1,249,115, June 2023), targeting STAT3 for non-small cell lung cancer prevention in COPD patients ($1,097,981, September 2022), and targeting the PARP pathway for breast cancer prevention ($1,121,090, June 2022). Additional orders span STAT3 targeting for colorectal cancer secondary to inflammatory bowel disease, real-time metabolic imaging biomarkers for pancreatic premalignant lesion detection, iPSC-based vaccine development for colorectal cancer, CD73 inhibitor testing for pancreatic cancer, STAT3 targeting for hepatocellular carcinoma associated with non-alcoholic steatohepatitis, cancer prevention by vaccination against induced antigens, clarithromycin repurposing for lung and breast cancer, and sulindac-erlotinib combination dosing optimization for gastrointestinal cancer prevention. All delivery orders are performed at MD Anderson's Houston location and self-performed without subcontractor engagement.
Task orders
Show all 13
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Additional Work (new agreement, FAR part 6 applies) | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 75N91019D00021?
75N91019D00021 was awarded to The Univeristy Of Texas M.d. Anderson Cancer Center by National Cancer Institute (National Institutes of Health) on January 25, 2019.
How much is contract 75N91019D00021 worth?
Orders under 75N91019D00021 have obligated $12,529,369. Their combined current value, with exercised options, is $13,778,484. 75N91019D00021's own ceiling is $74,995,000.
How many orders have been placed under contract 75N91019D00021?
13 orders have been placed under 75N91019D00021, the latest on September 15, 2023.
Who can order from contract 75N91019D00021?
75N91019D00021 is a multiple award indefinite delivery contract. Only the awarding agency can place orders on it.
Is contract 75N91019D00021 part of a contract vehicle?
Yes. 75N91019D00021 is part of PREVENT Preclinical Drug Development Program (PREVENT).
Was contract 75N91019D00021 competed?
The extent of competition for 75N91019D00021 was full and open competition. The government received 4 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV